Natriuretic and neurohormonal responses to nesiritide, furosemide, and combined nesiritide and furosemide in patients with stable systolic dysfunction

Clinical Cardiology

Volumn 33, Issue 6, 2010, Pages 330-336

  Sica, Domenic ^a   Oren, Ron M ^b   Gottwald, Mildred D ^c   Mills, Roger M ^c  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^c SCIOS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLIC GMP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; NATRIURETIC FACTOR; NESIRITIDE; NEUROHORMONE; POTASSIUM; SODIUM; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; LOOP DIURETIC AGENT;

ADULT; ALDOSTERONE BLOOD LEVEL; ANALYSIS OF COVARIANCE; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTINUOUS INFUSION; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CROSSOVER PROCEDURE; DEFIBRILLATOR; DIABETES MELLITUS; DIET; DIURESIS; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; FEMALE; FLUID INTAKE; HEADACHE; HEART ATRIUM ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE ARRHYTHMIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HORMONE RESPONSE; HUMAN; HYPOTENSION; MALE; MULTICENTER STUDY; NATRIURESIS; NAUSEA; OUTCOME ASSESSMENT; POSITIONAL DIZZINESS; POTASSIUM URINE LEVEL; RADIOIMMUNOASSAY; RIGOR; SODIUM URINE LEVEL; SYSTOLIC DYSFUNCTION; TRANSLUMINAL CORONARY ANGIOPLASTY; URINARY EXCRETION; URINE FLOW RATE; AGED; BLOOD; COMPARATIVE STUDY; COMPLICATION; DRUG COMBINATION; DRUG EFFECTS; DRUG RESISTANCE; ETIOLOGY; HEART VENTRICLE FUNCTION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SYSTOLE; TIME; TREATMENT OUTCOME; UNITED STATES;

ADULT; AGED; ALDOSTERONE; BIOLOGICAL MARKERS; CROSS-OVER STUDIES; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; FUROSEMIDE; HEART FAILURE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; NATRIURESIS; NATRIURETIC AGENTS; NATRIURETIC PEPTIDE, BRAIN; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; SYSTOLE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; VENTRICULAR DYSFUNCTION; VENTRICULAR FUNCTION;

EID: 77953863300     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20787     Document Type: Article

References (17)

1. Brater DC. Diuretic therapy in congestive heart failure. Congest Heart Fail. 2000;6:197-201. (Pubitemid 32937337)
2. Krämer BK, Schweda F, Riegger GA. Diuretic treatment and diuretic resistance in heart failure. Am J Med. 1999;106:90-96. (Pubitemid 29077144)
3. Ellison DH. Diuretic therapy and resistance in congestive heart failure. Cardiology. 2001;96:132-143. (Pubitemid 34114123)
4. Gottlieb SS, Brater DC, Thomas I, et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation. 2002;105:1348-1353.
5. Ravnan SL, Ravnan MC, Deedwania PC. Pharmacotherapy in congestive heart failure: diuretic resistance and strategies to overcome resistance in patients with congestive heart failure. Congest Heart Fail. 2002;8:80-85.
6. Gheorghiade M, Gattis WA, O'Connor CM, et al.; Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004;291:1963-1971.
7. DiDomenico RJ, Park HY, Southworth MR, et al. Guidelines for acute decompensated heart failure treatment[published correction appears in Ann Pharmacother. 2004;38:1092]. Ann Pharmacother. 2004;38:649-660.
8. Holmes SJ, Espiner EA, Richards AM, Yandle TG, Frampton C. Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab. 1993;76:91-96.
9. Jensen KT, Carstens J, Pedersen EB. Effect of BNP on renal hemodynamics, tubular function and vasoactive hormones in humans. Am J Physiol. 1998;274:F63-F72.
10. Yoshimura M, Yasue H, Morita E, et al. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation. 1991;84:1581-1588.
11. Pasquale PD, Sarullo FM, Paterna S. Novel strategies: challenge loop diuretics and sodium management in heart failure - Part I. Congest Heart Fail. 2007;13:93-98.
12. Brater DC. Pharmacology of diuretics. Am J Med Sci. 2000;319:38-50.
13. Sica DA, Gehr TW. Diuretic combinations in refractory oedema states: pharmacokinetic-pharmacodynamic relationships. Clin Pharmacokinet. 1996;30:229-249.
14. Ikram H, Chan W, Espiner EA, Nicholls MG. Haemodynamic and hormone responses to acute and chronic frusemide therapy in congestive heart failure. Clin Sci (Lond). 1980;59:443-449. (Pubitemid 11168352)
15. Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JN. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure: activation of the neurohumoral axis. Ann Intern Med. 1985; 103:1-6.
16. Bayliss J, Norell M, Canepa-Anson R, Sutton G, Poole-Wilson P. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J. 1987;57:17-22.
17. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82:1724-1729.